高齢者機能評価とレジメンでわかる　がん薬物療法

出版社： 中外医学社
著者：
発行日： 2022-09-30
分野： 臨床医学：一般  >  薬物療法
ISBN： 9784498117204
電子書籍版： 2022-09-30 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,280 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

高齢がん患者はそれぞれ多様な臨床背景をもち，薬物療法において容易に臨床試験のエビデンスを適用できないことも多い．本書の前半では，高齢がん患者の多様性や機能を客観的に評価するための具体的なツールを用い，どのように介入するかを解説．後半ではがん薬物療法の代表的なレジメンのコツと高齢者への注意点などを一目で分かるようにし，高齢者のがん薬物療法の実践の一助となる一冊となっている．

目次

  • I　高齢者のがん薬物療法の考え方

    A．高齢者の意思決定と有害事象の特徴
    　1．がん領域での高齢者機能評価
    　　1．高齢がん患者の治療方針決定
    　　2．高齢者機能評価とは
    　　3．ガイドラインでの推奨
    　　4．GAに基づくマネジメントの有用性
    　2．がん薬物療法を受ける高齢がん患者の意思決定支援
    　　1．がん薬物療法における高齢者支援の現状
    　　2．がん薬物療法を受ける高齢者のヘルスリテラシー
    　　3．高齢者の意思決定支援
    　　4．高齢者の意思決定能力を高めるコミュニケーションの工夫
    　3．高齢がん患者の有害事象の特徴とケア
    　　1．高齢者のがん薬物療法における有害事象の特徴
    　　2．治療開始前のアセスメントと介入
    　　3．患者教育
    　　4．セルフケア支援
    　　5．症状マネジメントとケア

    B．高齢者機能評価のドメインと評価ツール
    　1．生活機能
    　　1．パフォーマンスステータスについて
    　　2．日常生活動作（activities of daily living: ADL）
    　　3．手段的日常生活動作（instrumental activities of daily living: IADL）
    　　4．身体機能
    　　5．介入について
    　2．薬物療法を受ける高齢がん患者を対象とした運動療法
    　　1．運動療法の目的
    　　2．運動療法のリスク管理と注意点
    　　3．運動療法の実際
    　3．転倒・転落
    　　1．定義と予防の重要性
    　　2．発生状況
    　　3．要因
    　　4．がん薬物療法による転倒・転落リスクの増加
    　　5．転倒・転落リスクアセスメント
    　　6．転倒・転落を予防するためのケア
    　4．併存症〈千田彰彦，浜本康夫〉
    　　1．併存症を評価する意義
    　　2．併存症の評価法
    　　3．併存症をもつ患者への介入
    　5．栄養状態
    　　1．栄養管理の概要
    　　2．栄養障害のスクリーニング
    　　3．栄養アセスメント
    　　4．がんの病状・治療方針
    　6．食事指導
    　　1．高齢者のがん薬物療法と食事指導
    　　2．必要栄養量の算出と食事指導・栄養支援
    　　3．がん薬物療法施行時の有害事象と食事指導・栄養支援
    　　4．経口栄養補助食品（oral nutritional supplements：ONS）と食事指導・栄養支援
    　7．認知機能
    　　1．がん治療と認知機能
    　　2．認知機能検査とその役割
    　　3．主要な認知機能検査
    　　4．介入
    　　5．認知機能障害のある場合の対応
    　8．がん薬物療法とポリファーマシーについて
    　　1．ポリファーマシーの背景とその影響
    　　2．処方適正化のための基準
    　　3．がん薬物療法中のポリファーマシー対策と工夫
    　9．ポリファーマシーへの薬学的介入
    　　1．がん患者におけるポリファーマシーの問題点
    　　2．ポリファーマシーと薬学的介入の現状
    　　3．薬剤師の役割
    　10．服薬アドヒアランスと看護
    　　1．服薬アドヒアランスに影響を与える要因
    　　2．服薬を支援するためのアセスメント
    　　3．服薬アドヒアランスを高めるための看護師の役割
    　　4．服薬支援の実際
    　11．精神状態・気分
    　　1．高齢がん患者における気分障害の特徴
    　　2．評価ツール
    　　3．高齢がん患者に自記式質問票を用いる問題点
    　　4．高齢がん患者の抑うつに対する介入
    　12．社会的サポート
    　　1．高齢がん患者の社会的フレイル
    　　2．評価ツール
    　　3．高齢がん患者の社会的サポート介入

    C．高齢者機能評価スクリーニングツールと有害事象予測ツール
    　1．高齢者機能評価スクリーニングツール
    　2．高齢者機能評価を用いた有害事象予測ツール

    II　レジメンの実際と治療のコツ
    A．肺癌
    　1．非小細胞肺癌　ドライバー遺伝子変異陰性(1)
    　　1）細胞傷害性抗がん薬＋免疫チェックポイント阻害薬（ICI）
    　　2）カルボプラチン＋アルブミン懸濁型パクリタキセル
    　2．非小細胞肺癌　ドライバー遺伝子変異陰性(2)
    　　1）カルボプラチン＋ペメトレキセド
    　　2）免疫チェックポイント阻害薬単剤
    　3．非小細胞肺癌　ドライバー遺伝子変異陽性(1)
    　　1）オシメルチニブ単剤
    　　2）エルロチニブ+ラムシルマブ
    　4．非小細胞肺癌　ドライバー遺伝子変異陽性(2)
    　　1）ゲフィチニブ単剤
    　　2）カルボプラチン＋ペメトレキセド＋ゲフィチニブ
    　5．小細胞肺癌
    　　1）カルボプラチン+エトポシド
    　　2）アムルビシン

    B．消化器癌
    　1．胃癌　術後補助
    　　1）S-1，ドセタキセル＋S-1（DS）
    　　2）カペシタビン＋オキサリプラチン（CAPOX）
    　2．胃癌　転移再発
    　　1）S-1＋オキサリプラチン（SOX）
    　　2）ラムシルマブ＋パクリタキセル
    　3．大腸癌　術後補助
    　　1）カペシタビン単剤
    　　2）カペシタビン＋オキサリプラチン（CAPOX），FOLFOX
    　4．大腸癌　転移再発
    　　1）カペシタビン+ベバシズマブ
    　　2）セツキシマブ単剤またはパニツムマブ単剤
    　5．膵臓癌
    　　1）ゲムシタビン＋アルブミン懸濁型パクリタキセル
    　　2）フルオロウラシル＋レボホリナート＋リポソーム型イリノテカン

    C．乳癌
    　1．乳癌　術前・術後補助
    　　1）ドキソルビシン＋シクロホスファミド（AC）
    　　2）毎週パクリタキセル
    　2．ホルモン受容体陽性乳癌　転移再発
    　　1）アロマターゼ阻害薬単剤
    　　2）フルベストラント
    　3．乳癌　転移再発（抗HER2療法を除く(1)）
    　　1）エリブリン
    　　2）ベバシズマブ＋パクリタキセル
    　4．乳癌　転移再発（抗HER2療法を除く(2)）
    　　1）S-1単剤
    　　2）アテゾリズマブ＋アルブミン懸濁型パクリタキセル
    　5．HER2陽性乳癌　術後補助
    　　1）パクリタキセル＋トラスツズマブ
    　6．HER2陽性乳癌　転移再発
    　　1）ペルツズマブ＋トラスツズマブ＋ドセタキセル

    D．造血器腫瘍
    　1．悪性リンパ腫
    　　1）R-CHOP
    　　2）ベンダムスチン＋リツキシマブ（BR）
    　2．慢性リンパ性白血病（CLL），多発性骨髄腫
    　　1）慢性リンパ性白血病（CLL）：イブルチニブ単剤
    　　2）多発性骨髄腫（MM）：ダラツムマブ＋レナリドミド＋デキサメタゾン（DLd）

    E．泌尿器系腫瘍
    　1．前立腺癌　去勢抵抗性
    　　1）ドセタキセル＋プレドニゾロン
    　　2）カバジタキセル＋プレドニゾロン
    　2．腎癌
    　　1）アキシチニブ＋ペムブロリズマブ
    　　2）イピリムマブ＋ニボルマブ

    F．婦人科腫瘍
    　1．卵巣癌
    　　1）パクリタキセル+カルボプラチン（毎週分割投与，weekly TC）
    　　2）ゲムシタビン
    　2．子宮内膜癌
    　　1）ドキソルビシン＋シスプラチン（AP）
    　　2）パクリタキセル＋カルボプラチン（TC）
    　3．子宮頸癌
    　　1）パクリタキセル＋シスプラチン＋ベバシズマブ
    　　2）パクリタキセル＋カルボプラチン（TC）

    G．その他
    　1．原発不明がん
    　　1）パクリタキセル＋カルボプラチン
    　2．転移性脳腫瘍

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 高齢者のがん薬物療法の考え方

P.9 掲載の参考文献
1) National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology, Older Adult Oncology. https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf
 
2) 国立がん研究センター がん情報サービス年齢・全身状態別余命データ https://ganjoho.jp/med_pro/med_info/guideline/life_expectancy.html (2021年5月20日アクセス)
 
3) Appelbaum PS. Assessment of patients' competence to consent to treatment. N Engl J Med. 2007 ; 357 : 1834-40.
PubMed
4) Fried TR, Bradley EH, Towle VR, et al. Understanding the treatment preferences of seriously ill patients. N Eng J Med. 2002 ; 346 : 1061-6.
 
5) Reuben DB. Comprehensive geriatric assessment and system approaches to geriatric care. In : Cassel CK, Leipzig RM, Cohen HJ, et al, editors. Geriatric medicine, An evidence-based approach. 4h ed. New York : Springer Verlag ; 2004. p.195-204.
 
6) Ellis G, Whitehead MA, O'Neill D, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev. 2011 : Cd006211.
 
7) Wildiers H, Heeren H, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014 ; 32 : 2595.
 
8) Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients : the ONCODAGE Prospective Multicenter Cohort Study. PLoS One. 2014 ; 9 : e115060.
 
9) Saliba D, Elliot E, Rubenstein LZ, et al. The vulnerable elders survey : a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001 ; 49 : 1691.
 
10) Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016 ; 34 : 2366.
 
11) Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients : the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012 ; 118 : 3377.
 
12) 高齢者のための化学療法毒性予測ツール (CARG toxicity calculator 日本語版) https://cityofhope.worldsecuresystems.com/ctc/Chemo_Toxicity_Calculator_JA
 
13) Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy : ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018 ; 36 : 2326.
PubMed
14) 日本臨床腫瘍学会/日本癌治療学会, 編. 高齢者のがん薬物療法ガイドライン. 東京 : 南江堂 ; 2019.
 
15) Mohile SG, Mohamed MR, Xu H, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+) : a clusterrandomised study. Lancet. 2021 ; 398 : 1894-904.
 
16) Mohile SG, Epstein RM, Hunia A et al. Communication with older patients with cancer using geriatric assessment : A cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program. JAMA Oncol. 2019 ; 6 : 1-9.
 
17) Li D, Sun CL, Kim H, et al. Geriatric Assessment-Driven Intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer : A randomized clinical trial. JAMA Oncol. 2021 ; 7 : e214158.
 
18) Baitar A, Kenis C, Moor R, et al. Implementation of geriatric assessment-based recommendations in older patients with cancer : A multicenter prospective study. J Geriatr Oncol. 2015 ; 6 : 401-10.
 
19) Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment : a meta-analysis of controlled trials. Lancet. 1993 ; 342 : 1032-6.
PubMed
20) Magnuson A, Dale W, Mohile S. Models of care in geriatric oncology. Curr Geriatr Rep. 2014 ; 3 : 182-89.
PubMed
P.17 掲載の参考文献
1) がん研究振興財団. がんの統計 2022. 2022. p.56, p.90-1.
 
2) 内閣府. 平成29年版高齢社会白書.
 
3) 内閣府. 令和3年版高齢社会白書.
 
4) 太田喜久子. 老年看護学. 東京 : 医歯薬出版 ; 2012. p.52.
 
5) 府川晃子. 化学療法を受ける高齢がん患者のQOLに関する文献レビュー. 日本がん看護学会誌. 2017.
 
6) Boyd CM, Landefeld CS, Counsell, SR, et al. Recovery of activities of daily living in older adults after hospitalization for acute medical illness. J Am Geriatr Soc. 2008 : 56 ; 2171-9.
PubMed
7) 厚生労働省. 第3期がん対策推進基本計画. 参照先 : https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000196973.pdf (2021年7月19日確認).
 
8) 大鵬薬品工業. ティ-エスワンOD錠薬剤添付文書. 2022.
 
9) National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology older adult oncology. 2022. 参照先 : https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf (2022年6月7日確認)
 
10) Mislang AR, Wildes TM, Kanesvaran R, et al. Adherence to oral cancer therapy in older adults. The International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev. 2017 ; 57 : 58-66.
PubMed
11) 中山和弘. ヘルスリテラシーとは. In : 福田洋, 江口泰正. ヘルスリテラシー-健康教育の新しいキーワード. 東京 : 大修館書店 ; 2016. p.1-22.
 
12) Sorensen K, Van den Broucke K, Fullam J, et al. Health literacy and public health : a systematic review and integration of definitions and models. BMC Public Health. 2012 ; 12 : 80.
PubMed
13) Berkman ND, Sheridan SL, Donahue KE, et al. Health literacy interventions and outcomes : an updated systematic review. Evid Rep Technol Assess (Full Rep). 2011 ; 199 : 941.
 
14) Baker DW, Parker RM, Williams MV, et al. The health care experience of patients with low literacy. Arc Fam Med. 1996 ; 5 : 329.
 
15) Rigdon AS. Development of patient education for older adults receiving chemotherapy. Clin J Oncol Nursing. 2010 ; 14. 433-41.
 
16) 国立がん研究センター. 高齢者のがん診療における意思決定支援の手引き. 参照先 : https://www.ncc.go.jp/jp/epoc/division/psycho_oncology/kashiwa/research_summary/050/isikettei_pnf.pdf (2022年4月18日確認)
 
17) Weiss B. Health literacy and patient safety : Help patients understand. Manual for clinicians. American Medical Association Foundation. 2007.
 
P.27 掲載の参考文献
1) 小川朝生. 認知症をもつ高齢がん患者の特徴とアセスメントおよびケアのポイント. がん看護. 2016 ; 21 : 140-4.
 
2) 及川敦子. 高齢がん患者のがん化学療法による有害事象の特徴とセルフケアを支えるケア. がん看護. 2016 ; 21 : 196-200.
 
3) 日本がんサポーティブケア学会. 高齢者がん医療 Q&A 総論 ; 2020. p.53-4.
 
4) 酸化マグネシウム錠250 mg「ヨシダ」添付文書 ; 吉田製薬. 2019.
 
5) 日本がんサポーティブケア学会. 高齢者がん医療 Q&A 総論 ; 2020. p.116.
 
P.39 掲載の参考文献
1) Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy : ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018 ; 36 : 2326-47.
PubMed
2) World Health Organization. (2001). International classification of functioning, disability and health : ICF. World Health Organization. https://apps.who.int/iris/handle/10665/42407
 
3) Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948 ; 1 : 634-56.
 
4) Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 ; 5 : 649-55.
PubMed
5) Peus D, Newcomb N, Hofer S. Appraisal of the Karnofsky performance status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak. 2013 ; 13 : 72.
PubMed
6) Jolly TA, Deal AM, Nyrop KA, et al. Geriatric assessment-identified deficits in older cancer patients with normal performance status. Oncologist. 2015 ; 20 : 379-85.
PubMed
7) Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer : a prospective multicenter study. J Clin Oncol. 2011 ; 29 : 3457-65.
 
8) Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist. 1970 ; 10 : 20-30.
PubMed
9) Mahoney FI, Barthel DW. Functional evaluation : The Barthel Index. Md State Med J. 1965 ; 14 : 61-5.
PubMed
10) Fillenbaum GG. Multidimensional functional assessment of older adults : The Duke Older Americans Resources and Services procedures. Psychology Press ; 2013.
 
11) Lawton MP, Brody EM. Assessment of older people : self-maintaining and instrumental activities of daily living. Gerontologist. 1969 ; 9 : 179-86.
PubMed
12) Koyano W, Shibata H, Nakazato K, et al. Measurement of competence : reliability and validity of the TMIG Index of Competence. Arch Gerontol Geriatr. 1991 ; 13 : 103-16.
PubMed
13) Centers for Disease Control and Prevention (CDC) Timed Up & Go. https://www.cdc.gov/steadi/pdf/TUG_test-print.pdf (2022年6月9日 アクセス)
 
14) Nordin E, Lindelof N, Rosendahl E, et al. Prognostic validity of the Timed Up-and-Go test, a modified Get-Up-and-Go test, staff's global judgement and fall history in evaluating fall risk in residential care facilities. Age Ageing. 2008 ; 37 : 442-48.
 
15) Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function : association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994 ; 49 : M85-94.
 
16) Middleton A, Fritz SL, Lusardi M. Walking speed : the functional vital sign. J Aging Phys Act. 2015 ; 23 : 314-22.
PubMed
17) Cummings SR, Studenski S, Ferrucci L. A diagnosis of dismobility--giving mobility clinical visibility : a Mobility Working Group recommendation. JAMA. 2014 ; 311 : 2061-2.
 
18) Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia : 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020 ; 21 : 300-7 e302.
 
19) Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia : revised European consensus on definition and diagnosis. Age Ageing. 2019 ; 48 : 16-31.
PubMed
20) Naito T, Mitsunaga S, Miura S, et al. Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer. J Cachexia Sarcopenia Muscle. 2019 ; 10 : 73-83.
PubMed
P.49 掲載の参考文献
1) 長寿科学振興財団. 健康長寿ネット. https://www.tyojyu.or.jp/net/kenkou-tyoju/kenkou-undou/undou-ryouhou.html (cited : 2019-12)
 
2) 厚生労働省, e-ヘルスネット. https://www.e-healthnet.mhlw.go.jp/information/dictionary/exercise/ys-086.html (cited : 2019-12)
 
3) Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy : ASCO guideline for geriatric oncology. J Clin Oncol. 2018 ; 36 : 2326.
PubMed
4) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Older Adult Oncology. 2020.
 
5) Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey : a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001 ; 49 : 1691-9.
PubMed
6) Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients : first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012 ; 23 : 2166-72.
 
7) Van Roie E, Delecluse C, Coudyzer W, et al. Strength training at high versus low external resistance in older adults effects on muscle volume, muscle strength, and force-velocity characteristics. Exp gerontol. 2013 ; 48 : 1351-61.
PubMed
8) Csapo R, Alegre LM. Effects of resistance training with moderate vs heavy loads on muscle mass and strength in the elderly : A meta-analysis. Scand J Med & Sci in Sports. 2016 ; 26 : 995-1006.
 
9) 厚生労働省 アクティブガイド-健康づくりのための身体活動指針- https://www.mhlw.go.jp/stf/houdou/2r9852000002xple-att/2r9852000002xpr1.pdf (cited : 2019-12)
 
10) Schmitz KH, Courneya KS, Matthews C, et al. American college of sports medicine roundtable on exercise guidelines for cancer survivors. Med & Sci in Sports Exerc. 2010 ; 42 : 1409-26.
PubMed
11) Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in older adults : recommendation from the American College of Sports Medicine and the American Heart Association. Circulation. 2007 ; 116 : 1094-105.
PubMed
12) Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer : an update and emerging new evidence. Lancet Oncol. 2017 ; 18 : e457-71.
PubMed
13) Gobbens RJJ, vanAssen MA. The prediction of ADL and IADL disability using six physical indicators of frailty : a longitudinal study in the Netherlands. Current gerontology and geriatrics research. cited : 2022-4, doi.org/10.1155/2014/35817
 
14) Wang D XM, Yao J, Zirek Y, et al. Muscle mass, strength, and physical performance predicting activities of daily living : a meta-analysis. J Cachexia Sarcopenia Muscle. 2020 ; 11 : 3-25.
 
15) 長寿医療研究開発費事業 (27-23) : 要介護高齢者, フレイル高齢者, 認知症高齢者に対する栄養療法, 運動療法, 薬物療法に関するガイドライン作成に向けた調査研究班. フレイル診療ガイド 2018年版. 東京 : ライフ・サイエンス ; 2018.
 
16) Becker Cl, Kron M, Lindemann U, et al. Effectiveness of a multifaceted intervention on falls in nursing home residents. J Am Geriatr Soc. 2003 ; 51 : 306-13.
 
17) 日本リハビリテーション医学会. がんのリハビリテーション診療ガイドライン 第2版. 東京 : 金原出版 ; 2020.
 
18) Naito T, Okayama T, Aoyama T, et al. Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan : a prospective longitudinal observational study. BMC Cancer. 2017 ; 17 : 1-10.
PubMed
P.59 掲載の参考文献
1) World Health Organization 編, 鈴木みずえ, 金森雅夫, 中川経子, 監訳. In : WHO グローバルレポート 高齢者の転倒予防. 東京 : クオリティケア ; 2010. p.1.
 
2) 鈴木隆雄. 転倒の疫学. 日本老年医学会雑誌. 2003 ; 40 : 88.
 
3) 厚生労働省. 平成21年度「不慮の事故死亡統計」の概況 第9表 年齢階級別にみた不慮の事故の種類別死亡数及び構成割合. https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/usyu/furyo10/dl/gaikyo.pdf
 
4) 檜山明子, 中村惠子. 入院患者の転倒リスクが高い行動の分析. 日本看護研究学会雑誌. 2017 ; 40 : 659-61.
 
5) 帖佐悦男. 高齢者特有の医学的問題への対応 転倒・骨折. 臨床と研究. 2021 ; 98 : 83.
 
6) 五嶋佳子. 転倒予防体操. In : 中島洋子. スキルアップパートナーズ 病棟で生かす! 高齢者ケアの実践. 東京 : 照林社 ; 2012. p.207.
 
P.63 掲載の参考文献
1) Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies : development and validation. J Chron Dis. 1987 ; 40 : 373-83.
PubMed
2) Linn BS, Linn MW, Gurel L, et al. Cumulative Illness Rating Scale. J Am Geriatr Soc. 1968 ; 16 : 622-6.
PubMed
3) Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014 ; 32 : 2595-603.
 
4) Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006 ; 24 : 2368-75.
PubMed
5) Zauderer M, Patil S, Hurriaet A, et al. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat. 2009 ; 117 : 205-10.
PubMed
6) Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994 ; 47 : 1.
PubMed
7) Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968 ; 16 : 622-6.
PubMed
8) Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research : application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992 ; 41 : 237-48.
PubMed
9) Gronberg BH, Sundstrom S, Kaasa S, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010 ; 46 : 2225-34.
PubMed
P.71 掲載の参考文献
1) Muscaritoli M, Arends J, Aapro M. From guidelines to clinical practice : a roadmap for oncologists for nutrition therapy for cancer patients. Ther Adv Med Oncol. 2019 ; 11 : 1758835919880084.
PubMed
2) Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015 ; 33 : 90-9.
PubMed
3) Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017 ; 36 : 49-64.
PubMed
4) Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 ; 36 : 11-48.
PubMed
5) Muscaritoli M, Rossi Fanelli F, Molfino A. Perspectives of health care professionals on cancer cachexia : results from three global surveys. Ann Oncol. 2016 ; 27 : 2230-6.
PubMed
6) (NCCN) TNCCN. NCCN Guidelines for Specific Populations : Older Adult Oncology [Available from : https://www.nccn.org/professionals/physician_gls/default.aspx.
 
7) Roeland EJ, Bohlke K, Baracos VE, et al. Management of Cancer Cachexia : ASCO Guideline. J Clin Oncol. 2020 ; 38 : 2438-53.
PubMed
8) Boullata JI, Gilbert K, Sacks G, et al. A.S.P.E.N. clinical guidelines : parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enterol Nutr. 2014 ; 38 : 334-77.
 
9) Cederholm T, Jensen GL, Correia M, et al. GLIM criteria for the diagnosis of malnutrition-A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle. 2019 ; 10 : 207-17.
 
10) Karsegard VL, Ferlay O, Maisonneuve N, et al. Simplified malnutrition screening tool : Malnutrition Universal Screening Tool (MUST). Rev Med Suisse Romande. 2004 ; 124 : 601-5.
PubMed
11) Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition (Burbank, Los Angeles County, Calif). 1999 ; 15 : 116-22.
 
12) Dent E, Hoogendijk EO, Visvanathan R, et al. Malnutrition screening and assessment in hospitalised older people : a review. J Nutr Health Aging. 2019 ; 23 : 431-41.
PubMed
13) JCOG 高齢者研究委員会. 推奨高齢者機能評価ツール. http://wwwjcogjp/basic/org/committee/gschtml. 2016.
 
14) Garcia MV, Agar MR, Soo WK, et al. Screening tools for identifying older adults with cancer who may benefit from a geriatric assessment : A Systematic Review. JAMA Oncology. 2021 ; 7 : 616-27.
PubMed
15) Cederholm T, Jensen GL, Correia M, et al. GLIM criteria for the diagnosis of malnutrition-A consensus report from the global clinical nutrition community. Clin Nutr. 2019 ; 38 : 1-9.
PubMed
16) Jager-Wittenaar H, Ottery FD. Assessing nutritional status in cancer : role of the Patient-Generated Subjective Global Assessment. Curr Opin Clin Nutr Metab Care. 2017 ; 20 : 322-9.
PubMed
17) McMillan DC. The systemic inflammation-based Glasgow Prognostic Score : a decade of experience in patients with cancer. Cancer Treat Rev. 2013 ; 39 : 534-40.
 
18) Liposits G, Orrevall Y, Kaasa S, et al. Nutrition in cancer care : A brief, practical guide with a focus on clinical practice. JCO Oncol Pract. 2021 ; 17 : e992-8.
 
P.78 掲載の参考文献
1) 日本静脈経腸栄養学会, 編. In : 静脈経腸栄養ガイドライン 第3版. 東京 : 照林社 ; 2013. p.333-43.
 
2) Arends J, Bodoky G, Bozzetti F, et al. ESPEN Guidelines on Enteral Nutrition : Non-surgical oncology. Clin Nutr. 2006 ; 25 : 245-59.
PubMed
3) 伊藤貞嘉, 佐々木敏, 監修. 日本人の食事摂取基準 (2020年版). 厚生労働省「日本人の食事摂取基準」策定検討報告書. 東京 : 第一出版 ; 2020.
 
4) 日本静脈経腸栄養学会, 編. In : 静脈経腸栄養テキストブック. 東京 : 南江堂 ; 2017. p.436-42.
 
P.85 掲載の参考文献
1) Inouye SK, Peduzzi PN, Robison JT, et al. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA. 1998 ; 279 : 1187-93.
PubMed
2) Garcia-Ptacek S, Farahmand B, Kareholt I, et al. Mortality risk after dementia diagnosis by dementia type and underlying factors : A cohort of 15,209 patients based on the swedish dementia registry. J Alzheimers Dis. 2014 ; 41 : 467-77.
PubMed
3) Mayeda ER, Glymour MM, Quesenberry CP, et al. Survival after dementia diagnosis in five racial/ethnic groups. Alzheimers Dement. 2017 ; 13 : 761-9.
PubMed
4) 厚生労働省. Https://www.Mhlw.Go.Jp/content/000524702.Pdf.
 
5) Lunney JR, Lynn J, Foley DJ, et al. Patterns of functional decline at the end of life. JAMA. 2003 ; 289 : 2387-92.
PubMed
6) Raji MA, Kuo YF, Freeman JL, et al. Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer : Implications for cancer care. Arch Intern Med. 2008 ; 168 : 2033-40.
PubMed
7) Network NCC. NCCN clinical practice guidelines in oncology, older adult oncology version 1.2020. 2020.
 
8) Tombaugh TN, McIntyre NJ. The mini-mental state examination : A comprehensive review. J Am Geriatr Soc. 1992 ; 40 : 922-35.
PubMed
9) 杉下守弘, 腰塚洋介, 須藤慎治, 他. Mmse-j (精神状態短時間検査-日本語版) 原法の妥当性と信頼性. 認知神経科学. 2018 ; 20 : 91-110.
 
10) 加藤伸司, 長谷川和夫, 下垣光. 改訂長谷川式簡易知能評価スケール (HDS-R) の作成. 老年精神医学雑誌. 1991 ; 2 : 1339-47.
Medical*Online
11) Shulman KI. Clock-drawing : Is it the ideal cognitive screening test? Int J Geriatr Psychiatry. 2000 ; 15 : 548-61.
PubMed
12) Nasreddine ZS, Phillips NA, Bedirian V, et al. The montreal cognitive assessment, moca : A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 ; 53 : 695-9.
 
13) Borson S, Scanlan J, Brush M, et al. The mini-cog : A cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000 ; 15 : 1021-7.
PubMed
14) Katzman R, Brown T, Fuld P, et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983 ; 140 : 734-9.
 
15) Kawas C, Karagiozis H, Resau L, et al. Reliability of the blessed telephone information-memory-concentration test. J Geriatr Psychiatry Neurol. 1995 ; 8 : 238-42.
 
16) 粟田主一. 地域包括ケアシステムにおける認知症総合アセスメントDASC-21標準テキスト. 東京 : メディア・ケアプラス ; 2016.
 
17) 厚生労働省. 認知症の人の日常生活・社会生活における意思決定支援ガイドライン. 2018. Available at https://www.mhlw.go.jp/content/000524702.pdf. (2022年6月7日アクセス)
 
P.92 掲載の参考文献
1) Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ. 2008 ; 336 : 606-9.
PubMed
2) Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007 ; 5 : 345-51.
PubMed
3) Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education : a cross-sectional study. Lancet. 2012 ; 380 : 37-43.
PubMed
4) 厚生労働省. 高齢者の医薬品適正使用の指針 (各論編 療養環境別) について. 医政安発0614 第1号 : https://www.mhlw.go.jp/content/11120000/000568037.pdf (2020年4月24日)
 
5) Kojima T, Akishita M, Nakamura T, et al. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012 ; 12 : 245-30.
 
6) Kojima T, Akishita M, Kameyama Y, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs : analysis of inpatient database. Geriatr Gerontol Int. 2012 ; 12 : 761-2.
PubMed
7) 日本老年医学会. 高齢者の安全な薬物療法ガイドライン 2015. 東京 : メジカルビュー社 ; 2015.
 
8) Jyrkka J, Enlund H, Lavikainen P, et al. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011 ; 20 : 514-22.
 
9) American Geriatrics Society 2019 Updated AGS Beers Criteria? for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019 ; 67 : 674-94.
PubMed
10) O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people : version 2. Age Ageing. 2015 ; 44 : 213-8.
 
11) 今井博久, Beers MH, Fick DM, 他. 高齢患者における不適切な薬剤処方の基準-Beers Criteriaの日本版の開発. 日本医師会雑誌. 2008 ; 137 : 84-91.
 
12) 国立保健医療科学院疫学部. 高齢者は避けて欲しい薬のリスト (2008年4月1日付新聞掲載). Available from : http://www.niph.go.jp/soshiki/ekigaku/BeersCriteriaJapan.pdf
 
13) Hill-Taylor B, Walsh KA, Stewart S, et al. Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria : systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016 ; 41 : 158-69.
 
14) Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992 ; 45 : 1045-51.
PubMed
15) Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest. 2006 ; 24 : 704-12.
PubMed
16) Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Can Inst. 2007 ; 99 : 592-600.
PubMed
17) Mohile SG, Mohamed M, Culkova E, et al. A geriatric Assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer : A University of Rochester Cancer Center NCI Community Oncology Research Program cluster randomized controlled trial (CRCT). ASCO 2020 #12009 (302115).
 
18) Mizokami F, Mizuno T, Kanamori K, et al. Clinical medication review type III of polypharmacy reduced unplanned hospitalizations in older adults : A meta-analysis of randomized clinical trials. Geriatr Gerontol Int. 2019 ; 19 : 1275-81.
 
P.102 掲載の参考文献
1) Hersh LR, Beldowski K, Hajjar ER. Polypharmacy in the geriatric oncology population. Curr Oncol Rep. 2017 ; 19 : 73.
 
2) Onda M, Imai H, Takada Y, et al. Identification and prevalence of adverse drug events caused by potentially inappropriate medication in homebound elderly patients : a retrospective study using a nationwide survey in Japan. BMJ Open. 2015 ; 5 : e007581.
PubMed
3) Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004 ; 52 : 1349-54.
PubMed
4) Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 ; 353 : 487-97.
PubMed
5) Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance : a meta-analysis. The Am J Med. 2007 ; 120 : 713-9.
 
6) Leelakanok N, Holcombe AL, Lund BC, et al. Association between polypharmacy and death : A systematic review and meta-analysis. JAPhA. 2017 ; 57 : 729-38.e10.
 
7) Uchida M, Suzuki S, Sugawara H, et al. A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan. J Pharm Health Care Sci. 2019 ; 5 : 14.
PubMed
8) Suzuki S, Uchida M, Suga Y, et al. A Nationwide survey of community pharmacist contributions to polypharmacy in opioid-using and non-using cancer patients in Japan. Biol Pharm Bull. 2019 ; 42 : 1164-71.
PubMed
9) 日本老年学会, 編. 高齢者の安全な薬物療法ガイドライン 2015.
 
10) Lees J, Chan A. Polypharmacy in elderly patients with cancer : clinical implications and management. Lancet Oncol. 2011 ; 12 : 1249-57.
PubMed
P.110 掲載の参考文献
1) 厚生労働省. 高齢者の医薬品適正使用の指針 各論編 (療養環境別). 2019. p.8.
 
2) 厚生労働省. 高齢者の医薬品適正使用の指針 総論編. 2018. p.15.
 
3) 聖隷嚥下チーム. In : 摂食嚥下訓練の実際. 嚥下障害ポケットマニュアル. 4版. 東京 : 医歯薬出版 ; 2018. p.132.
 
4) 日本がん看護学会, 日本臨床腫瘍学会, 日本臨床腫瘍薬学会. がん薬物療法における職業性曝露対策ガイドライン. 2版. 東京 : 金原出版 ; 2019. p.117.
 
P.120 掲載の参考文献
1) 川上憲人 (主任研究者). 精神疾患の有病率等に関する大規模疫学調査研究 : 世界精神保健日本調査セカンド 2016. Available from : http://wmhj2.jp/WMHJ2-2016R.pdf.
 
2) Uchitomi Y, Mikami I, Nagai K, et al. Depression and psychological distress in patients during the year after curative resection of non-small-cell lung cancer. J Clin Oncol. 2003 ; 21 : 69-77.
PubMed
3) Akechi T, Okamura H, Nishiwaki Y, et al. Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma : a longitudinal study. Cancer. 2001 ; 92 : 2609-22.
PubMed
4) Minagawa H, Uchitomi Y, Yamawaki S, et al. Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer. 1996 ; 78 : 1131-7.
PubMed
5) Akechi T, Okuyama T, Uchida M, et al. Clinical indicators of depression among ambulatory cancer patients undergoing chemotherapy. Jpn J Clin Oncol. 2012 ; 42 : 1175-80.
PubMed
6) Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991 ; 38 : 143-62.
PubMed
7) Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1992 ; 4 : 134-9.
PubMed
8) 岡田和悟, 小林祥泰, 青木耕, 他. やる気スコアを用いた脳卒中後の意欲低下の評価. 脳卒中. 1998 ; 20 : 318-23.
Medical*Online
9) American Psychiatric Association. Depressive disorders. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington : American Psychiatric Publishing ; 2013.
 
10) 福田一彦, 小林重雄. 自己評価式抑うつ性尺度の研究. 精神神経学雑誌. 1973 ; 75 : 673-9.
 
11) Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961 ; 4 : 561-71.
PubMed
12) Kojima M, Furukawa TA, Takahashi H, et al. Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Res. 2002 ; 110 : 291-9.
PubMed
13) Radloff LS. The CES-D Scale : A self-report depression scale for research in the general population. Applied Psychological Measurement. 1977 ; 1 : 385-401.
 
14) 島悟, 鹿野達男, 北村俊則. 新しい抑うつ性自己評価尺度について. 精神医学. 1985 ; 27 : 717-23.
 
15) Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 ; 67 : 361-70.
PubMed
16) 北村俊則. Hospital Anxiety And Depression Scale (HAD尺度). 精神科診断学. 1993 ; 4 : 371-2.
 
17) Kugaya A, Akechi T, Okuyama T, et al. Screening for psychological distress in Japanese cancer patients. Jpn J Clin Oncol. 1998 ; 28 : 333-8.
PubMed
18) Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994 ; 272 : 1749-56.
PubMed
19) Kroenke K, Spitzer RL, Williams JB. The PHQ-9 : validity of a brief depression severity measure. J Gen Intern Med. 2001 ; 16 : 606-13.
PubMed
20) 村松公美子, 上島国利. プライマリ・ケア診療とうつ病スクリーニング評価ツール Patient Health Questionnaire-9 日本語版「こころとからだの質問票」について. 診断と治療. 2009 ; 97 : 1465-73.
 
21) Brink TL. Screening tests for geriatric depression. Clin Gerontol. 1982 ; 1 : 37-43.
 
22) Sheikh JI. Geriatric depression scale (GDS) : recent evidence and development of a shorter version. Clin Gerontol. 1986 ; 5 : 165-73.
 
23) 松林公蔵, 小澤利男. 総合的日常生活機能評価法-I 評価の方法. d 老年者の情緒に関する評価. Geriatric Medicine. 1994 ; 32 : 541-6.
Medical*Online
24) 杉下守弘, 朝田隆. 高齢者用うつ尺度短縮版-日本版 (Geriatric Depression Scale-Short Version-Japanese, GDS-S-J) の作成について. 認知神経科学. 2009 ; 11 : 87-90.
 
25) Sugishita K, Sugishita M, Hemmi I, et al. A Validity and Reliability Study of the Japanese Version of the Geriatric Depression Scale 15 (GDS-15-J). Clin Gerontol. 2017 ; 40 : 233-40.
 
26) Tsoi KK, Chan JY, Hirai HW, et al. Comparison of diagnostic performance of Two-Question Screen and 15 depression screening instruments for older adults : systematic review and meta-analysis. Br J Psychiatry. 2017 ; 210 : 255-60.
PubMed
27) Akizuki N, Yamawaki S, Akechi T, et al. Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Symptom Manage. 2005 ; 29 : 91-9.
PubMed
28) Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999 ; 48 : 1531-48.
PubMed
29) van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry. 1996 ; 169 : 440-3.
PubMed
30) Razavi D, Allilaire JF, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand. 1996 ; 94 : 205-10.
PubMed
31) Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression : a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003 ; 21 : 4635-41.
 
32) Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients : a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003 ; 21 : 1937-43.
 
33) Stockler MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression : a placebo-controlled double-blind randomised trial. Lancet Oncol. 2007 ; 8 : 603-12.
 
34) Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity : a patient-level meta-analysis. JAMA. 2010 ; 303 : 47-53.
PubMed
35) Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants and benzodiazepines in minor depression : systematic review and meta-analysis. Br J Psychiatry. 2011 ; 198 : 11-6, sup 1.
 
36) 高橋三郎, 大野裕, 監訳. DSM-5(R) 精神疾患の診断・統計マニュアル. 東京 : 医学書院 ; 2014
 
P.128 掲載の参考文献
1) 1 高齢化の現状と将来像-平成30年版高齢社会白書 (全体版) -内閣府 2021. Available from : https://www8.cao.go.jp/kourei/whitepaper/w-2018/html/zenbun/s1_1_1.html.
 
2) 3 家族と世帯-平成30年版高齢社会白書 (全体版) -内閣府 2021. Available from : https://www8.cao.go.jp/kourei/whitepaper/w-2018/html/zenbun/s1_1_3.html.
 
3) Yamada M, Arai H. Social frailty predicts incident disability and mortality among community-dwelling Japanese older adults. J Am Med Dir Assoc. 2018 ; 19 : 1099-103.
 
4) 小泉弥生, 粟田主一, 関徹, 他. 都市在住の高齢者におけるソーシャル・サポートと抑うつ症状の関連性. 日本老年医学会雑誌. 2004 ; 41 : 426-33.
 
5) Koizumi Y, Awata S, Kuriyama S, et al. Association between social support and depression status in the elderly : results of a 1-year community-based prospective cohort study in Japan. Psychiatry Clin Neurosci. 2005 ; 59 : 563-9.
PubMed
6) 村岡義明. うつ状態を呈する地域在宅高齢者の身体状況について. 精神医学. 1997 ; 39 : 285-90.
 
7) Awata S, Seki T, Koizumi Y, et al. Factors associated with suicidal ideation in an elderly urban Japanese population : a community-based, cross-sectional study. Psychiatry Clin Neurosci. 2005 ; 59 : 327-36.
 
8) Fujita K, Fujiwara Y, Chaves PH, et al. Frequency of going outdoors as a good predictors for incident disability of physical function as well as disability recovery in community-dwelling older adults in rural Japan. J Epidemiol. 2006 ; 16 : 261-70.
PubMed
9) Clark DO, Stump TE, Wolinsky FD. Predictors of onset of and recovery from mobility difficulty among adults aged 51-61 years. Am J Epidemiol. 1998 ; 148 : 63-71.
PubMed
10) Krause N. Social support, stress, and well-being among older adults. J Gerontol. 1986 ; 41 : 512-9.
PubMed
11) Cutrona C, Russell D, Rose J. Social support and adaptation to stress by the elderly. Psychol Aging. 1986 ; 1 : 47-54.
PubMed
12) Colantonio A, Kasl SV, Ostfeld AM, et al. Psychosocial predictors of stroke outcomes in an elderly population. J Gerontol. 1993 ; 48 : S261-8.
 
13) Frasure-Smith N, Lesperance F, Gravel G, et al. Social support, depression, and mortality during the first year after myocardial infarction. Circulation. 2000 ; 101 : 1919-24.
PubMed
14) 日本老年医学会. フレイルに関する日本老年医学会からのステートメント 2014 [Available from : https://www.jpn-geriat-soc.or.jp/info/topics/pdf/20140513_01_01.pdf.
 
15) 藤原佳典. 社会的フレイルの定義と介入策のあり方. Geriatr Med. 2017 ; 55 : 23-5.
Medical*Online
16) Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991 ; 32 : 705-14.
PubMed
17) Lubben JE. Assessing social networks among elderly populations. Family & Community Health : The Journal of Health Promotion & Maintenance. 1988 ; 11 : 42-52.
 
18) Berkman LF, Syme SL. Social networks, host resistance, and mortality : a nine-year follow-up study of Alameda County residents. Am J Epidemiol. 1979 ; 109 : 186-204.
PubMed
19) Ceria CD, Masaki KH, Rodriguez BL, et al. The relationship of psychosocial factors to total mortality among older Japanese-American men : the Honolulu Heart Program. J Am Geriatr Soc. 2001 ; 49 : 725-31.
 
20) Martire LM, Schulz R, Mittelmark MB, et al. Stability and change in older adults' social contact and social support : the Cardiovascular Health Study. J Gerontol B Psychol Sci Soc Sci. 1999 ; 54 : S302-11.
PubMed
21) Okwumabua JO, Baker FM, Wong SP, et al. Characteristics of depressive symptoms in elderly urban and rural African Americans. J Gerontol A Biol Sci Med Sci. 1997 ; 52 : M241-6.
 
22) Lubben J, Blozik E, Gillmann G, et al. Performance of an abbreviated version of the Lubben Social Network Scale among three European community-dwelling older adult populations. Gerontologist. 2006 ; 46 : 503-13.
PubMed
23) Heitzmann CA, Kaplan RM. Assessment of methods for measuring social support. Health Psychol. 1988 ; 7 : 75-109.
PubMed
24) 栗本鮎美, 粟田主一, 大久保孝義, 他. 日本語版 Lubben Social Network Scale 短縮版 (LSNS-6) の作成と信頼性および妥当性の検討. 日本老年医学会雑誌. 2011 ; 48 : 149-57.
 
25) 野口裕二. 高齢者のソーシャルサポート--その概念と測定. 社会老年学. 1991 : 37-48.
 
26) Zimet GD, Dahlem NW, Zimet SG, et al. The multidimensional scale of perceived social support. Journal of Personality Assessment. 1988 ; 52 : 30-41.
 
27) 岩佐一, 権藤恭之, 増井幸恵. 日本語版「ソーシャル・サポート尺度」の信頼性ならびに妥当性--中高年者を対象とした検討. 厚生の指標. 2007 ; 54 : 26-33.
 
P.138 掲載の参考文献
1) Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014 ; 32 : 2595-603.
 
2) Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients : an update on SIOG recommendations. Ann Oncol. 2015 ; 26 : 288-300.
PubMed
3) Garcia MV, Agar MR, Soo W, et al. Screening tools for identifying older adults with cancer who may benefit from a geriatric assessment : A systematic review. JAMA Oncol. 2021 ; 7 : 616-27.
PubMed
4) Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients : first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012 ; 23 : 2166-72.
 
5) van Walree IC, Scheepers E, van Huis-Tanja L, et al. A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer. J Geriatr Oncol. 2019 ; 10 : 847-58.
 
6) Liuu E, Canoui-Poitrine F, Tournigand C, et al. Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site : the ELCAPA-02 study. J Geriatr Oncol. 2014 ; 5 : 11-9.
 
7) Mizutani T, Nakamura K, Fukuda H, et al. Geriatric Research Policy : Japan Clinical Oncology Group (JCOG) policy. Jpn J Clin Oncol. 2019 ; 49 : 901-10.
PubMed
8) Kenis C, Decoster L, Van Puyvelde K, et al. Performance of two geriatric screening tools in older cancer patients. J Clin Oncol. 2014 ; 32 : 19-26.
 
9) Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients : the ONCODAGE Prospective Multicenter Cohort Study. PLoS One. 2014 ; 9 : e115060.
 
10) Takahashi M, Takahashi M, Komine K, et al. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients : A retrospective, single institutional study. PLoS One. 2017 ; 12 : e0179694.
PubMed
11) Takahashi M, Sakamoto Y, Ohori H, et al. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401) : geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers. Cancer Chemother Pharmacol. 2021 ; 88 : 393-402.
PubMed
12) Agemi Y, Shimokawa T, Sasaki J, et al. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer : A single-institution study. PLoS One. 2019 ; 14 : e0210499.
PubMed
13) Lund CM, Vistisen KK, Olsen AP, et al. The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer : a randomised trial (GERICO). Br J Cancer. 2021 ; 124 : 1949-58.
PubMed
14) Saliba D, Elliott M, Rubenstein LZ, et al. The vulnerable elders survey : a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001 ; 49 : 1691-9.
PubMed
15) Biganzoli L, Mislang AR, Di Donato S, et al. Screening for frailty in older patients with early-stage solid tumors : A prospective longitudinal evaluation of three different geriatric tools. J Gerontol A Biol Sci Med Sci. 2017 ; 72 : 922-8.
PubMed
16) Owusu C, Margevicius S, Schluchter M, et al. Vulnerable elders survey and socioeconomic status predict functional decline and death among older women with newly diagnosed nonmetastatic breast cancer. Cancer. 2016 ; 122 : 2579-86.
PubMed
17) Luciani A, Biganzoli L, Colloca G, et al. Estimating the risk of chemotherapy toxicity in older patients with cancer : The role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol. 2015 ; 6 : 272-9.
PubMed
18) Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer : a prospective multicenter study. J Clin Oncol. 2011 ; 29 : 3457-65.
 
19) Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016 ; 34 : 2366-71.
 
20) Cancer and Aging Research Group (CARG). 高齢者のための化学療法毒性予測ツール. [https://cityofhope.worldsecuresystems.com/ctc/chemo_toxicity_calculator_JA]
 
21) Magnuson A, Sedrak MS, Gross CP, et al. Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer. J Clin Oncol. 2021 ; 39 : 608-18.
PubMed
22) Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients : the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012 ; 118 : 3377-86.
 

II レジメンの実際と治療のコツ

P.144 掲載の参考文献
1) Miyauchi E, Inoue A, Usui K, et al. Phase II study of modified carboplatin plus weekly nab-paclitaxel on elderly patients with non-small cell lung cancer : North Japan Lung Cancer Study Group trial 1301. Oncologist. 2017 ; 22 : 640-e59.
 
2) 日本肺癌学会, 編. 肺癌診療ガイドライン 2021年版. 2021. https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3 (2022年4月7 日閲覧)
 
3) Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 ; 378 : 2078-92.
PubMed
4) West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 ; 20 : 924-37.
PubMed
5) Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 ; 379 : 2040-51.
PubMed
P.148 掲載の参考文献
1) Hamamoto Y, Kogure Y, Kada A, et al. Randomised phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer : CAPITAL study. ASCO2021, abstract #9031.
 
2) Miyauchi E, Inoue A, Usui K, et al. Phase II study of modified carboplatin plus weekly nab-paclitaxel on elderly patients with non-small cell lung cancer : North Japan Lung Cancer Study Group trial 1301. Oncologist. 2017 ; 22 : 640-e59.
 
P.152 掲載の参考文献
1) Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 ; 26 : 3543-51.
PubMed
2) Rodrigues-Pereira J, Kim JH, Magallanes M, et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 ; 6 : 1907-14.
PubMed
3) Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE : randomized, open-label, phase III study of first-line pemetrexed+carboplatin followed by maintenance pemetrexed versus paclitaxel+carboplatin+bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 ; 10 : 134-42.
PubMed
4) Okamoto I, Nokihara H, Nomura S, et al. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer : A phase 3 randomized clinical trial. JAMA Oncol. 2020 ; 6 : e196828.
PubMed
P.154 掲載の参考文献
1) Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1positive advanced nonsmall-cell lung cancer : Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019 ; 135 : 188-95.
PubMed
P.157 掲載の参考文献
1) 日本肺癌学会, 編. 肺癌診療ガイドライン 2020年版. 東京 : 金原出版 ; 2020.
 
2) Furuta H, Uemura T, Yoshida T, et al. Efficacy and safety data of osimertinib in elderly patients with NSCLC Who Harbor the EGFR T790M mutation after failure of initial EGFR-TKI treatment. Anticancer Res. 2018 ; 38 : 5231-7.
PubMed
3) Nakao A, Hiranuma O, Uchino J, et al. Final results from a phase II trial of osimertinib for elderly patients with epidermal growth factor receptor t790m-positive non-small cell lung cancer that progressed during previous treatment. J Clin Med. 2020 ; 9 : 1762.
 
4) Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 ; 376 : 629-40.
 
5) Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor : AURA3 overall survival analysis. Ann Oncol. 2020 ; 31 : 1536-44.
PubMed
6) Ewer MS, Tekumalla SH, Walding A, et al. Cardiac safety of osimertinib : A review of data. J Clin Oncol. 2021 ; 39 : 328-37.
 
P.159 掲載の参考文献
1) 日本肺癌学会, 編. 肺癌診療ガイドライン 2020年版. 東京 : 金原出版 ; 2020.
 
2) Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 ; 20 : 1655-69.
PubMed
3) Nishio M, Seto T, Reck M, et al. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer : East Asian subset of RELAY. Cancer Sci. 2020 ; 111 : 4510-25.
 
P.162 掲載の参考文献
1) Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006 ; 24 : 2549-56.
PubMed
2) Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 ; 362 : 2380-8.
 
3) Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol. 2010 ; 11 : 121-8.
PubMed
4) Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations : NEJ 003 study. J Thorac Oncol. 2012 ; 7 : 1417-22.
PubMed
5) Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009 ; 27 : 1394-400.
PubMed
6) Satoh H, Inoue A, Kobayashi K, et al. Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol. 2011 ; 6 : 1413-7.
PubMed
P.165 掲載の参考文献
1) Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor : NEJ009 study. J Clin Oncol. 2020 ; 38 : 115-23.
PubMed
2) Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020 ; 38 : 124-36.
PubMed
3) 日本肺癌学会. 肺癌診療ガイドライン 2021年版. 2021.
 
4) Okamoto I, Nokihara H, Nomura, et al. Comparison of carboplatin plus peme trexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer : A phase 3 randomized clinical trial. JAMA Oncol. 2020 ; 6 : e196828.
 
P.169 掲載の参考文献
1) Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer : JCOG 9702. Br J Cancer. 2007 ; 97 : 162-9.
PubMed
2) Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 ; 379 : 2220-9.
PubMed
3) Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 ; 394 : 1929-39.
PubMed
P.172 掲載の参考文献
1) von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014 ; 32 : 4012-9.
PubMed
2) Horita N, Yamamoto M, Sato T, et al. Amrubicin for relapsed small-cell lung cancer : a systematic review and meta-analysis of 803 patients. Sci Rep. 2016 ; 6 : 18999.
PubMed
3) Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011 ; 29 : 287-93.
PubMed
4) Imai H, Sugiyama T, Tamura T, et al. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. Cancer Chemother Pharmacol. 2017 ; 80 : 615-22.
 
5) Igawa S, Ono T, Kasajima M, et al. Impact of amrubicin monotherapy as second-line chemotherapy on outcomes in elderly patients with relapsed extensive-disease small-cell lung cancer. Cancer Manag Res. 2020 ; 12 : 4911-21.
PubMed
P.176 掲載の参考文献
1) Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 ; 29 : 4387-93.
PubMed
2) Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer : interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019 ; 37 : 1296-304.
PubMed
P.179 掲載の参考文献
1) Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) : 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 1389-96.
PubMed
2) Nakamura Y, Yamanaka T, Chin K, et al. Survival outcomes of two phase 2 studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin for patients with gastric cancer after D2 gastrectomy. Ann Surg Oncol. 2019 ; 26 : 465-72.
PubMed
P.182 掲載の参考文献
1) Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag. 2005 ; 1 : 249-58.
PubMed
2) Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015 ; 26 : 141-8.
 
3) Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial. Lancet Oncol. 2008 ; 9 : 215-21.
 
4) Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 ; 358 : 36-46.
PubMed
5) Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer : a systematic review and meta-analysis. Gastric Cancer. 2011 ; 14 : 50-5.
PubMed
6) Bando H, Yamada Y, Tanabe S, et al. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer. 2016 ; 19 : 919-26.
 
P.185 掲載の参考文献
1) Wilke H, Muro K, Van Cutsem E, et al ; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW) : a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 1224-35.
 
2) Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial. J Clin Oncol. 2013 ; 31 : 4438-44.
 
3) Fuchs CS, Tomasek J, Yong CJ, et al ; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 ; 383 : 31-9.
PubMed
4) Muro K, Cho JY, Bodoky G, et al. Age does not influence efficacy of ramucirumab in advanced gastric cancer : Subgroup analyses of REGARD and RAINBOW. J Gastroenterol Hepatol. 2018 ; 33 : 814-24.
PubMed
P.188 掲載の参考文献
1) 日本臨床腫瘍学会/日本癌治療学会, 編. 高齢者のがん薬物療法ガイドライン. 東京 : 南江堂 ; 2019.
 
2) 大腸癌研究会, 編. 大腸癌治療ガイドライン 医師用 2019年版. 東京 : 金原出版 ; 2019.
 
3) Twelves C, Scheithauer W, Mckendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer : final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamics marker of efficacy. Ann Oncol. 2012 ; 23 : 1190-7.
PubMed
P.193 掲載の参考文献
1) McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer. Findings from the ACCENT database. J Clin Oncol. 2013 ; 31 : 2600-6.
PubMed
2) Haller DG, O'Connell MJ, Cartwright TH, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer : a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol. 2015 ; 26 : 715-24.
 
3) Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018 ; 378 : 1177-88.
PubMed
4) Yoshino T, Yamanaka T, Oki E, et al. Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer : The ACIEVE phase 3 randomized clinicaltrial. JAMA Oncol. 2019 ; 5 : 1574-81.
 
5) Andre T, Boni C, Navarro M, et a. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 ; 27 : 3109-16.
PubMed
P.196 掲載の参考文献
1) 大腸癌治療ガイドライン 医師用 2019年版. 東京 : 金原出版 ; 2019. p.34-8.
 
2) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines R) Colon Cancer Version 2.2021, https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
 
3) Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX) : an open-label, randomised phase 3 trial. Lancet Oncol. 2013 ; 14 : 1077-85.
PubMed
P.199 掲載の参考文献
1) 大腸癌治療ガイドライン 医師用 2022年版. 東京 : 金原出版 ; 2019. p.34-42.
 
2) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines R) Colon Cancer Version 2. 2021, https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
 
3) Sastre J, Massuti B, Pulido G, et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors : A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer. 2015 ; 51 : 1371-80.
 
4) Pietrantonio F, Cremolini C, Aprile G, et al. Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer : Challenging drug label to light up new hope. Oncologist. 2015 ; 20 : 1261-5.
PubMed
5) Sastre J, Aranda E, Gravalos C, et al. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. 2011 ; 77 : 78-84.
 
6) Kobayashi Y, Komatsu Y, Yuki S, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer : HGCSG1001 study ; J-STEPP. Future Oncol. 2015 ; 11 : 617-27.
PubMed
P.202 掲載の参考文献
1) Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 ; 369 : 1691-703.
PubMed
P.205 掲載の参考文献
1) Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) : a global, randomised, open-label, phase 3 trial. Lancet. 2016 ; 387 : 545-57.
PubMed
P.208 掲載の参考文献
1) Early Breast Cancer Trialists' Collaborative Group ; Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer : meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012 ; 379 : 432-44.
 
2) Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 ; 360 : 2055-65.
PubMed
3) Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer : the results of 20 years of follow-up. N Engl J Med. 1995 ; 332 : 901-6.
PubMed
4) Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 ; 33 : 3199-212.
 
5) Abdel-Qadir H, Austin PC, Lee DS, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2017 ; 2 : 88-93.
PubMed
P.211 掲載の参考文献
1) Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer : results from NSABP B-28. J Clin Oncol. 2005 ; 23 : 3686-96.
PubMed
2) Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 ; 21 : 976-83.
PubMed
3) Martin M, Rodriguez-Lescure A, Ruiz A, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008 ; 100 : 805-14.
 
4) Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 ; 358 : 1663-71.
PubMed
5) Sparano JA, Zhao F, Martino S, et al. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015 ; 33 : 2353-60.
PubMed
6) Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006 ; 24 : 1633-42.
PubMed
7) Tanabe Y, Hashimoto K, Shimizu C, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013 ; 18 : 132-8.
PubMed
8) Tanabe Y, Shimizu C, Hamada A, et al. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol. 2017 ; 79 : 1179-86.
PubMed
P.215 掲載の参考文献
1) Mauri D, Pavlidis N, Polyzos NP, et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer : meta-analysis. J Natl Cancer Inst. 2006 ; 98 : 1285-91.
PubMed
2) Xu HB, Liu YJ, Li L. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer : a literature-based meta-analysis. Clin Breast Cancer. 2011 ; 11 : 246-51.
PubMed
3) Tang SC. Women and bone health : maximizing the benefits of aromatase inhibitor therapy. Oncology. 2010 ; 79 : 13-6.
PubMed
4) Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 ; 21 : 4042-57.
 
5) Jenkins VA, Ambroisine LM, Atkins L, et al. Effects of anastrozole on cognitive performance in postmenopausal women : a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol. 2008 ; 9 : 953-61.
PubMed
6) Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer : results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010 ; 28 : 1294-300.
 
P.217 掲載の参考文献
1) Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON) : an international, randomised, double-blind, phase 3 trial. Lancet. 2016 ; 388 : 2997-3005.
PubMed
P.220 掲載の参考文献
1) Cortes J, O'Shaughnessy J, Loesch D, et al ; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE) : a phase 3 open-label randomised study. Lancet. 2011 ; 377 : 914-23.
 
2) Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 ; 33 : 594-601.
 
3) Muss H, Cortes J, Vahdat LT, et al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist. 2014 ; 19 : 318-27.
 
P.223 掲載の参考文献
1) Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 ; 357 : 2666-76.
PubMed
2) Pivot X, Schneeweiss A, Verma S, et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer : results from AVADO. Eur J Cancer. 2011 ; 47 : 2387-95.
PubMed
3) Biganzoli L, Di Vincenzo E, Jiang Z, et al. First-line bevacizumab-containing therapy for breast cancer : results in patients aged?70 years treated in the ATHENA study. Ann Oncol. 2012 ; 23 : 111-8.
PubMed
P.226 掲載の参考文献
1) Takashima T, Mukai H, Hara F, et al. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2016 ; 17 : 90-8.
PubMed
2) Makiyama A, Kunieda K, Noguchi M, et al. First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer : a multicenter propensity score matched study. Gastric Cancer. 2018 ; 21 : 792-801.
PubMed
3) Imai H, Minemura H, Kishikawa T, et al. Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ?75 years) with non-small cell lung cancer : A retrospective analysis. Thorac Cancer. 2020 ; 11 : 2867-76.
PubMed
4) Kimura Y, Kikkawa N, Iijima S, et al. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session : efficacy and feasibility in clinical practice. Gastric Cancer. 2003 ; 6 Suppl 1 : 34-9.
PubMed
P.229 掲載の参考文献
1) Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 ; 379 : 2108-21.
PubMed
2) Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130) : updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 ; 21 : 44-59.
 
3) 日本乳癌学会. 乳がん診療ガイドライン 2018年版 Ver.5/2021年3月31日改訂. 東京 : 金原出版 ; 2021.
 
P.232 掲載の参考文献
1) Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 ; 372 : 134-41.
PubMed
2) Sawaki M, Taira N, Uemura Y, et al. Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients. J Clin Oncol. 2020 ; 38 : 3743-52.
 
P.235 掲載の参考文献
1) Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 ; 366 : 109-19.
PubMed
2) Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 ; 372 : 724-34.
PubMed
3) Ando M, Watanabe T, Nagata K, et al. Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol. 2001 ; 19 : 336-42.
 
4) Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 ; 33 : 442-7.
PubMed
P.239 掲載の参考文献
1) Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 ; 346 : 235-42.
PubMed
2) Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 ; 7 : 379-91.
PubMed
3) Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 ; 9 : 105-16.
PubMed
4) Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma : a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 ; 381 : 1817-26.
 
5) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版補訂版. 東京 : 金原出版 ; 2020. p. 244-5.
 
6) Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma : a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011 ; 12 : 460-8.
PubMed
7) 大間知謙. CHOP/R-CHOP療法. In : 飛内賢正, 他編. 悪性リンパ腫治療マニュアル. 改訂第5版. 東京 : 南江堂 ; 2020. p.249-53.
 
8) Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma : Clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303. J Clin Oncol. 2019 ; 37 : 1790-9.
 
9) BC Cancer Agency <http://www.bccancer.bc.ca/> accessed 9 May 2021.
 
P.243 掲載の参考文献
1) Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008 ; 26 : 4473-9.
PubMed
2) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 ; 381 : 1203-10.
PubMed
3) Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013 ; 31 : 2103-9.
PubMed
4) Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020 ; 38 : 155-65.
 
5) 大間知謙. bendamustine/bendamustine-R療法. In : 飛内賢正, 他編. 悪性リンパ腫治療マニュアル. 改訂第5版. 東京 : 南江堂 ; 2020. p.254-5.
 
P.247 掲載の参考文献
1) Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 ; 34 : 787-98.
PubMed
2) Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018 ; 379 : 2517-28.
PubMed
3) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版 補訂版. 東京 : 金原出版 ; 2020.
 
P.251 掲載の参考文献
1) Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019 ; 380 : 2104-15.
PubMed
2) Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 ; 375 : 1319-31.
PubMed
3) Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020 ; 34 : 1875-84.
PubMed
P.254 掲載の参考文献
1) Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 ; 351 : 1502-12.
 
2) Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer : a randomised, phase 3 trial. Lancet Oncol. 2013 ; 14 : 117-24.
PubMed
P.256 掲載の参考文献
1) de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet. 2010 ; 376 : 1147-54.
PubMed
2) Nozawa M, Mukai H, Takahashi S, et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol. 2015 ; 20 : 1026-34.
PubMed
3) Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017 ; 35 : 3198-206.
PubMed
P.259 掲載の参考文献
1) キイトルーダ適正使用ガイド (最終閲覧日 : 2021年4月19日) Available from : https://www.msdconnect.jp/static/mcijapan/images/properuse_guide_keytruda.pdf
 
2) インライタ適正使用ガイド 2020年2月改訂 (第6版) (最終閲覧日 : 2021年4月19日) Available from : https://pfizerpro.jp/documents/info/inl01info.pdf
 
3) Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 ; 380 : 1116-27.
PubMed
4) Powels T, Plimack ER, Soulieres D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426) : extended follow-up from a randomized, open-label, phase 3 trial. Lancet Oncol. 2020 ; 21 : 1563-73.
 
5) Miyake H, Harada K, Ozono S, et al. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma. Med Oncol. 2016 ; 33 : 95.
PubMed
P.262 掲載の参考文献
1) オプジーボ・ヤーボイ適正使用ガイド (2020年12月10日アップロード, 最終閲覧 2021年4月19日) Available from : https://www.opdivo.jp/system/files/2021-01/opd_guide_combi_0.pdf
 
2) Motzer RJ, Tannir NM, Aren Frontera O, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 ; 378 : 1277-90.
PubMed
3) Araujo DV, Wells JC, Hansen AR, et al. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) -an International mRCC Database Consortium (IMDC) analysis. J Geriatr Oncol, https://doi.org/10.1016/j.jgo.2021.02.022
 
4) Elias E, Odejide O. Immunotherapy in older adults : A checkpoint to palliation? Society of Clinical Oncology Educational Book 39 (May 17, 2019) e110-20.
 
5) Kanesvaran R, Le Saux O, Matzer R, et al. Elderly patients with metastatic renal cell carcinoma : position paper from the International Society of Geriatric Oncology. Lancet Oncol. 2018 ; 19 : e317-26.
 
P.265 掲載の参考文献
1) du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003 ; 95 : 1320-9.
 
2) Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : a Gynecologic Oncology Group study. J Clin Oncol. 2003 ; 21 : 3194-200.
 
3) Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016) : a randomised, controlled, open-label trial. The Lancet Oncology. 2013 ; 14 : 1020-6.
PubMed
4) Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 ; 365 : 2484-96.
PubMed
5) Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 ; 365 : 2473-83.
PubMed
6) Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7) : a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology. 2014 ; 15 : 396-405.
PubMed
7) Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018 ; 379 : 2495-505.
PubMed
8) Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019 ; 381 : 2391-402.
PubMed
P.269 掲載の参考文献
1) Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007 ; 25 : 2811-8.
PubMed
2) Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008 ; 26 : 890-6.
PubMed
P.272 掲載の参考文献
1) Nomura H, Aoki D, Michimae H, et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression : A randomized clinical trial. JAMA Oncol. 2019 ; 5 : 833-40.
 
2) Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer : final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 ; 38 : 3841-50.
PubMed
P.274 掲載の参考文献
1) Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer : Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 ; 38 : 3841-50.
PubMed
P.277 掲載の参考文献
1) Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 ; 370 : 734-43.
PubMed
P.279 掲載の参考文献
1) Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer : The open-label randomized phase III Trial JCOG0505. J Clin Oncol. 2015 ; 33 : 2129-35.
 
P.284 掲載の参考文献
1) Wildes TM, Dua P, Fowler SA, et al. Systematic review of falls in older adults with cancer. J Geriatr Oncol. 2015 ; 6 : 70-83.
 
2) Hess KR, Abbruzzese MC, Lenzi R, et al. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999 ; 5 : 3403-10.
PubMed
3) Wood AJJ, Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknownprimary site. N Engl J Med. 1993 ; 329 : 257-63.
 
4) Occult Primary (Cancer of Unknown Primary [CUP]), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). 2021.
 
5) Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations : NEJ 003 study. J Thorac Oncol. 2012 ; 7 : 1417-22.
PubMed
6) Goto K, Nishio M, Yamamoto N, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer [Internet]. 2013 ; 82 : 109-14. Available from : http://dx.doi.org/10.1016/j.lungcan.2013.07.003
 
7) Kubo T, Watanabe H, Ninomiya K, et al. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Jpn J Clin Oncol [Internet]. 2020 ; 50 : 1447-53. Available from : https://academic.oup.com/jjco/article/50/12/1447/5899736
 
8) Ninomiya K, Oze I, Kato Y, et al. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers : a systematic review and meta-analysis. Acta Oncol (Madr) [Internet]. 2020 ; 59 : 249-56. Available from : https://www.tandfonline.com/doi/full/10.1080/0284186X.2019.1695062
 
9) Hayashi H, Kurata T, Takiguchi Y, et al. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol. 2019 ; 37 : 570-9.
PubMed
10) Hayashi H, Takiguchi Y, Minami H, et al. Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site. JAMA Oncol [Internet]. 2020 ; 6 : 1931. Available from : https://jamanetwork.com/journals/jamaoncology/fullarticle/2771755
 
11) Tanizaki J, Yonemori K, Akiyoshi K, et al. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol. 2022 ; 33 : 216-26.
PubMed
12) Amela EY, Lauridant-Philippin G, Cousin S, et al. Management of "unfavourable" carcinoma of unknown primary site : Synthesis of recent literature. Crit Rev Oncol Hematol [Internet]. 2012 ; 84 : 213-23. Available from : https://linkinghub.elsevier.com/retrieve/pii/S1040842812000698
 
13) Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma : A phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol. 2000 ; 18 : 3101-7.
 
14) Huebner G, Link H, Kohne CH, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno-or undifferentiated carcinoma of unknown primary : A randomised prospective phase II trial. Br J Cancer. 2009 ; 100 : 44-9.
PubMed
15) Lee J, Hahn S, Kim DW, et al. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary : A systematic review and meta-analysis. Br J Cancer. 2013 ; 108 : 39-48.
PubMed
16) Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer : IFCT-0501 randomised, phase 3 trial. Lancet. 2011 ; 378 : 1079-88.
PubMed
P.290 掲載の参考文献
1) Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases : epidemiology. Handb Clin Neurol. 2018 ; 149 : 27-42.
PubMed
2) Rapp SR, Case LD, Peiffer A, et al. Donepezil for irradiated brain tumor survivors : A phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015 ; 33 : 1653-9.
PubMed
3) Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomised controlled trial. Lancet Oncology. 2009 ; 10 : 1037-44.
PubMed
4) Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases : Phase III trial NRG oncology CC001. J Clini Oncol. 2020 ; 38 : 1019-29.
 
5) Brain Tumor Registry of Japan (2005-2008). Neurologia medico-chirurgica. 2017 ; 57 (Supplement-1) : 9-102.
 
6) 中川和彦, 監. 奥田武司, 中洲庸子, 編. 転移性脳腫瘍診断・治療・管理マニュアル. 大阪 : メディカ出版 ; 2014.
 
7) Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 ; 37 : 745-51.
PubMed
8) Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases : an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008 ; 70 : 510-4.
PubMed
9) Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA. 2006 ; 295 : 2483-91.
PubMed
10) Kepka L, Tyc-Szczepaniak D, Bujko K, et al. Stereotactic radiotherapy of the tumor bed compared to whole brain radiotherapy after surgery of single brain metastasis : Results from a randomized trial. Radiother Oncol. 2016 ; 121 : 217-24.
PubMed
11) Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007 ; 68 : 1388-95.
PubMed
12) Ebi J, Sato H, Nakajima M, et al. Incidence of leukoencephalopathy after whole-brain radiation therapy for brain metastases. Int J Radiat Oncol Biol Phys. 2013 ; 85 : 1212-7.
PubMed
13) Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases : analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011 ; 6 : 48.
PubMed
14) Socha J, Rychter A, Kepka L. Management of brain metastases in elderly patients with lung cancer. J Thorac Dis. 2021 ; 13 : 3295-307.
PubMed
15) 日本脳腫瘍学会. 脳腫瘍診療ガイドライン 2019年版. 2019.
 

書評

最近チェックした商品履歴

Loading...